Porcine CD 40 Ligand ELISA Kit

B cell depletion via anti-CD20 antibodies is a highly effective treatment for multiple sclerosis (MS). However, little is known about the maturation/activation stage of the returning B cell population after treatment cessation and the wider effects on other immune cells. In the present study, 15 relapsing-remitting MS patients receiving 1,000 mg of rituximab were included. B, T, and myeloid cells were analyzed before anti-CD20 administration and in different time intervals thereafter over a period of 24 mo. In comparison to the phenotype before anti-CD20 treatment, the reappearing B cell pool revealed a less mature and more activated phenotype: 1) reappearing B cells were significantly enriched in transitional (before: 10.1 +/- 1.9%, after: 58.8 +/- 5.2%) and mature naive phenotypes (before: 45.5 +/- 3.1%, after: 25.1 +/- 3.5%); 2) the frequency of memory B cells was reduced (before: 36.7 +/- 3.1%, after: 8.9 +/- 1.7%); and 3) reappearing B cells showed an enhanced expression of activation markers CD25 (before: 2.1 +/- 0.4%, after: 9.3 +/- 2.1%) and CD69 (before: 5.9 +/- 1.0%, after: 21.4 +/- 3.0%), and expressed significantly higher levels of costimulatory CD40 and CD86. T cells showed 1) a persistent increase in naive (CD4(+): before: 11.8 +/- 1.3%, after: 18.4 +/- 3.4%; CD8(+): before: 12.5 +/- 1.4%, after: 16.5 +/- 2.3%) and 2) a decrease in terminally differentiated subsets (CD4(+): before: 47.3 +/- 3.2%, after: 34.4 +/- 3.7%; CD8(+): before: 53.7 +/- 2.1%, after: 49.1 +/- 2.7%).

Survival rates after heart transplant have significantly improved over the last decade. Nevertheless, long-term allograft viability after 10 years remains poor and the sequelae of transplant-associated immunosuppression increases morbidity. Although several studies have implicated roles for lymphocyte-mediated rejection, less is understood with respect to non-major histocompatibility, and innate immune reactivity, which influence graft viability. As immature and mature dendritic cells (DCs) engage in both Major Histocompatibility Complex (MHC)-dependent and MHC-independent immune responses, these cells are at the crossroads of therapeutic strategies that seek to achieve both allograft tolerance and suppression of innate immunity to the allograft. Here we review emerging roles of DC subsets and their molecular protagonists during allograft tolerance and allograft rejection, with a focus on cardiac transplant. New insight into emerging DC subsets in transplant will inform novel strategies for operational tolerance and amelioration of cardiac vasculopathy.